Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
Colorcon
Johnson and Johnson
McKesson

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Us Worldmeds Llc Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for US WORLDMEDS LLC, and when can generic versions of US WORLDMEDS LLC drugs launch?

US WORLDMEDS LLC has four approved drugs.

There are three US patents protecting US WORLDMEDS LLC drugs.

There are eighty patent family members on US WORLDMEDS LLC drugs in thirty-one countries and ten supplementary protection certificates in nine countries.

Summary for Us Worldmeds Llc
International Patents:80
US Patents:3
Tradenames:4
Ingredients:4
NDAs:4

Drugs and US Patents for Us Worldmeds Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes 8,283,380   Start Trial   Start Trial
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes 8,076,515   Start Trial Y Y   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial
Us Worldmeds Llc MELPHALAN HYDROCHLORIDE melphalan hydrochloride INJECTABLE;INJECTION 207032-001 May 3, 2019 DISCN No No   Start Trial   Start Trial
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes   Start Trial   Start Trial
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No 8,283,380   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Us Worldmeds Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-002 Approved Prior to Jan 1, 1982 3,935,267   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-005 Oct 28, 1986 3,935,267   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-003 Approved Prior to Jan 1, 1982 3,982,021   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-005 Oct 28, 1986 3,982,021   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-002 Approved Prior to Jan 1, 1982 3,982,021   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-001 Approved Prior to Jan 1, 1982 3,982,021   Start Trial
Us Worldmeds Llc CORGARD nadolol TABLET;ORAL 018063-001 Approved Prior to Jan 1, 1982 3,935,267   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Us Worldmeds Llc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1613296 300752 Netherlands   Start Trial PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296 241 50017-2015 Slovakia   Start Trial PRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226
1613296 CA 2015 00042 Denmark   Start Trial PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
1613296 122015000058 Germany   Start Trial PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296 C20150033 00258 Estonia   Start Trial PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015
1613296 15C0054 France   Start Trial PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296 92782 Luxembourg   Start Trial PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Merck
Colorcon
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.